In PRAD, higher WSB2 expression positively correlated with key clinical parameters such as Gleason score (Figure 7B), pathological stage (Figure 7C), clinical stage (Figure 7D), and nodal metastasis status (Figure 7E). This evidence concerns the gene WSB2 and prostate adenocarcinoma.